InsiderTrades.com logo
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.

Francis Ostronic Biography and Net Worth

Director of Cyclo Therapeutics
  • Phone
  • Email
  • Website


Mr. Ostronic is an officer of US Pharmacia International, Inc., a subsidiary of USP, and also serves as the Chief Financial Officer of The USP Group. Mr. Ostronic is also a director of Novit US, Inc., the general partner of Novit.

What is Francis Patrick Ostronic's net worth?

The estimated net worth of Francis Patrick Ostronic is at least $106,806.95 as of September 21st, 2022. Mr. Ostronic owns 150,687 shares of Cyclo Therapeutics stock worth more than $106,807 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Ostronic may own. Learn More about Francis Patrick Ostronic's net worth.

How do I contact Francis Patrick Ostronic?

The corporate mailing address for Mr. Ostronic and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]. Learn More on Francis Patrick Ostronic's contact information.

Has Francis Patrick Ostronic been buying or selling shares of Cyclo Therapeutics?

Francis Patrick Ostronic has not been actively trading shares of Cyclo Therapeutics during the past quarter. Most recently, on Wednesday, September 21st, Francis Patrick Ostronic bought 5,000 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $1.76 per share, with a total value of $8,800.00. Following the completion of the transaction, the director now directly owns 150,687 shares of the company's stock, valued at $265,209.12. Learn More on Francis Patrick Ostronic's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Francis Patrick Ostronic Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2022Buy5,000$1.76$8,800.00150,687View SEC Filing Icon  
9/21/2022Buy5,000$1.76$8,800.00150,687View SEC Filing Icon  
5/20/2022Buy5,000$2.04$10,200.00138,525View SEC Filing Icon  
1/24/2022Buy2,000$3.75$7,500.00View SEC Filing Icon  
1/19/2022Buy1,132$4.00$4,528.00View SEC Filing Icon  
1/14/2022Buy2,137$4.00$8,548.00View SEC Filing Icon  
12/15/2021Buy3,000$3.90$11,700.00View SEC Filing Icon  
12/3/2021Buy864$4.75$4,104.00View SEC Filing Icon  
12/1/2021Buy5,000$5.00$25,000.00View SEC Filing Icon  
11/19/2021Buy10,652$5.25$55,923.00View SEC Filing Icon  
10/29/2021Buy1,000$5.90$5,900.00View SEC Filing Icon  
4/16/2021Buy10,000$6.53$65,300.0071,559View SEC Filing Icon  
4/12/2021Buy5,000$7.00$35,000.00
12/17/2020Buy30,000$4.66$139,800.00
See Full Table

Francis Patrick Ostronic Buying and Selling Activity at Cyclo Therapeutics

This chart shows Francis Patrick Ostronic's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More

Today's Range

Now: $0.71
Low: $0.69
High: $0.71

50 Day Range

MA: $0.72
Low: $0.61
High: $0.81

2 Week Range

Now: $0.71
Low: $0.59
High: $2.12

Volume

7,828 shs

Average Volume

21,546 shs

Market Capitalization

$20.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.